Company / R&D Expense
MIMEDX GROUP, INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$15.1M
FY2025
5-year range
$9.9M / $15.1M
FY2021-FY2025
Trend
+22.3%
vs FY2024
Sector context
#95 of 105
Health Care
What the data says
Among 105 Health Care companies, MIMEDX GROUP, INC. is in the bottom 10% for r&d expense. R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $15M.
Based on SEC 10-K filings.
$15M in FY2025 with a 5-year CAGR of +5.2%.
Improved from $13M to $15M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +5.9%
- 5-Year CAGR
- +5.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 105This company $15.1M Sector average $283.8M
▼
-94.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.2%, indicating consistent growth.
- In FY2025, r&d expense increased 22.3% year-over-year.
- Ranks #95 out of 105 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 3.50 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.1M | +22.3% |
| FY2024 | $12.3M | -2.6% |
| FY2023 | $12.7M | -0.3% |
| FY2022 | $12.7M | +27.9% |
| FY2021 | $9.9M | -15.2% |
| FY2020 | $11.7M | +5.2% |
| FY2019 | $11.1M | -29.3% |
| FY2018 | $15.8M | -11.9% |
| FY2017 | $17.9M | +24.8% |
| FY2016 | $14.3M | +70.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026